GlassScriptPhysician profile
Callie S Parry
NPI 1790347128
$6,858.08
in general payments reported to CMS, 2019-2025
31 companies · $3,227 in 2025
The $3,227 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $470 · 2022: $948 · 2023: $1,279 · 2024: $934 · 2025: $3,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217 · Travel and Lodging: $2,025 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.56 |
| Travel and Lodging | $2,025.37 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,819.71 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System |
| Intuitive Surgical, INC. | $878.78 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $835.10 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $600.47 | 2021-2024 | Arexvy, Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $294.04 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $249.52 | 2021-2024 | Glassia, Hyqvia |
| Genzyme Corporation | $230.32 | 2022-2024 | |
| Amgen INC. | $213.31 | 2022-2024 | Tezspire |
| Davol INC. | $162.39 | 2025 | Phasix Mesh |
| Merz North America, INC. | $153.29 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.56 | 2021-2025 | Ofev |
| Abiomed | $133.45 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $123.78 | 2021-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $113.40 | 2022-2025 | Tyvaso, Tyvaso |
| Abbvie INC. | $109.96 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $107.82 | 2022-2025 | Keytruda, Zerbaxa, Recarbrio |
| Insmed, INC. | $101.15 | 2023 | Arikayce |
| Medical Device Business Services, INC. | $98.00 | 2025 | |
| Inogen, INC. | $78.60 | 2023-2024 | Inogen |
| Mallinckrodt Hospital Products INC. | $77.43 | 2022-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $56.35 | 2023-2024 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $43.70 | 2023-2025 | Sunosi |
| Baxter Healthcare | $37.38 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Vapotherm INC | $34.49 | 2021 | |
| Shionogi INC | $32.46 | 2021-2023 | Fetroja |
| Paragon 28, INC. | $30.51 | 2025 | Precision Mis Bunion |
| Electromed, INC. | $25.09 | 2023 | Smartvest |
| Grifols USA, LLC | $23.75 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.10 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.26 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.